Indexed keywords
1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL;
2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE;
5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE;
AM 374;
ANANDAMIDE;
CANNABIDIOL;
CANNABINOID;
CANNABINOID 1 RECEPTOR;
CANNABINOID 2 RECEPTOR;
CANNABINOID RECEPTOR;
CANNABINOID RECEPTOR AGONIST;
CANNABINOID RECEPTOR ANTAGONIST;
N (4 HYDROXY PHENYL)ARACHIDONYLAMINE;
N (4 HYDROXYPHENYL)ARACHIDONYLETHANOLAMIDE;
PALMITYL SULFONYL FLUORIDE;
RECEPTOR SUBTYPE;
RIMONABANT;
TETRAHYDROCANNABINOL;
UNCLASSIFIED DRUG;
ALLERGIC ENCEPHALOMYELITIS;
ANIMAL MODEL;
DRUG ANTAGONISM;
HUMAN;
MULTIPLE SCLEROSIS;
NONHUMAN;
NOTE;
PRIORITY JOURNAL;
SPASTICITY;
TREMOR;
1
0001978419
The pharmacohistory of Cannabis sativa
R. Mechoulam The pharmacohistory of Cannabis sativa R. Mechoulam Cannabinoids as Therapeutic Agents 1986 CRS Press 1 19
(1986)
, pp. 1-19
Mechoulam, R.1
2
0025325535
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
L.A. Matsuda Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561 564
(1990)
Nature , vol.346
, pp. 561-564
Matsuda, L.A.1
3
0027515373
Molecular characterization of a peripheral receptor for cannabinoids
S. Munro Molecular characterization of a peripheral receptor for cannabinoids Nature 365 1993 61 65
(1993)
Nature , vol.365
, pp. 61-65
Munro, S.1
4
33947489961
Isolation, structure and partial synthesis of an active constituent of hashish
Y. Gaoni R. Mechoulam Isolation, structure and partial synthesis of an active constituent of hashish J. Am. Chem. Soc 86 1964 1646 1647
(1964)
J. Am. Chem. Soc , vol.86
, pp. 1646-1647
Gaoni, Y.1
Mechoulam, R.2
6
0034594905
Cannabinoids control spasticity and tremor in a multiple sclerosis model
D. Baker Cannabinoids control spasticity and tremor in a multiple sclerosis model Nature 404 2000 84 87
(2000)
Nature , vol.404
, pp. 84-87
Baker, D.1
7
0032451280
Brain cannabinoid systems as targets for the therapy of neurological disorders
P. Consroe Brain cannabinoid systems as targets for the therapy of neurological disorders Neurobiol. Dis 5 1998 534 551
(1998)
Neurobiol. Dis , vol.5
, pp. 534-551
Consroe, P.1
8
0028950529
Nabilone in the treatment of multiple sclerosis
C.N. Martyn Nabilone in the treatment of multiple sclerosis Lancet 345 1995 579
(1995)
Lancet , vol.345
, pp. 579
Martyn, C.N.1
9
0032401036
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
V. Di Marzo Endocannabinoids endogenous cannabinoid receptor ligands with neuromodulatory action Trends Neurosci 21 1998 521 528
(1998)
Trends Neurosci , vol.21
, pp. 521-528
Di Marzo, V.1
10
0031739073
Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of diskinesia in Parkinson’s disease
J.M. Brotchie Adjuncts to dopamine replacement a pragmatic approach to reducing the problem of diskinesia in Parkinson’s disease Mov. Disord 13 1998 871 876
(1998)
Mov. Disord , vol.13
, pp. 871-876
Brotchie, J.M.1
11
0030611978
Pharmacology of cannabinoid CB1 and CB2 receptors
2 receptors Pharmacol. Ther 74 1997 129 180
(1997)
Pharmacol. Ther , vol.74
, pp. 129-180
Pertwee, R.G.1
12
0033986604
Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells
R.A. Puffenbarger Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells Glia 29 2000 58 69
(2000)
Glia , vol.29
, pp. 58-69
Puffenbarger, R.A.1
13
0033936028
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease
V. Di Marzo Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease FASEB J. 2000 (in press)
(2000)
FASEB J.
Di Marzo, V.1
14
0026969158
Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from Δ9-tetrahydrocannabinol
9-tetrahydrocannabinol J. Pharmacol. Exp. Ther 263 1992 1118 1126
(1992)
J. Pharmacol. Exp. Ther , vol.263
, pp. 1118-1126
Compton, D.R.1
15
0032468166
Anandamide, an endogenous cannabinoid, has a very low physical dependence potential
M.D. Aceto Anandamide, an endogenous cannabinoid, has a very low physical dependence potential J. Pharmacol. Exp. Ther 287 1998 598 605
(1998)
J. Pharmacol. Exp. Ther , vol.287
, pp. 598-605
Aceto, M.D.1
16
0032766027
The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?
D.M. Lambert V. Di Marzo The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr. Med. Chem. 6 1999 757 773
(1999)
Curr. Med. Chem. , vol.6
, pp. 757-773
Lambert, D.M.1
Di Marzo, V.2
17
0032784084
Cannabimimetic fatty acid derivatives: the anandamide family and other ‘endocannabinoids’
V. Di Marzo Cannabimimetic fatty acid derivatives the anandamide family and other ‘endocannabinoids’ Curr. Med. Chem 6 1999 721 744
(1999)
Curr. Med. Chem , vol.6
, pp. 721-744
Di Marzo, V.1
18
0033538579
Structure–activity relationships of anandamide, an endogenous cannabinoid ligand
A.D. Khanolkar A. Makriyannis Structure–activity relationships of anandamide, an endogenous cannabinoid ligand Life Sci 65 1999 607 616
(1999)
Life Sci , vol.65
, pp. 607-616
Khanolkar, A.D.1
Makriyannis, A.2
19
0031830516
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity
S. Ben-Shabat An entourage effect inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity Eur. J. Pharmacol 353 1998 23 31
(1998)
Eur. J. Pharmacol , vol.353
, pp. 23-31
Ben-Shabat, S.1
20
0032537734
Control of pain initiation by endogenous cannabinoids
A. Calignano Control of pain initiation by endogenous cannabinoids Nature 394 1998 277 281
(1998)
Nature , vol.394
, pp. 277-281
Calignano, A.1
21
0033665922
Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders
V. Di Marzo Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders Chem. Phys. Lipids 2000 (in press)
(2000)
Chem. Phys. Lipids
Di Marzo, V.1
22
0031866598
The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler’s murine encephalomyelitis virus by a receptor-mediated pathway
F. Molina-Holgado The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler’s murine encephalomyelitis virus by a receptor-mediated pathway FEBS Lett 433 1998 139 142
(1998)
FEBS Lett , vol.433
, pp. 139-142
Molina-Holgado, F.1
